Manufacturers Trader Service

R-Biopharm AG

An der neuen Bergstr. 17 , 64297 Darmstadt
Germany

Telephone +49 6151 8102-0
Fax +49 6151 8102-40
info@r-biopharm.de

Trade fair hall

  • Hall 3 / B20
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 3): stand B20

Fairground map

MEDICA 2016 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic

Gene tests / molecular biological diagnostic

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.01  Allergies

Allergies

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases

Auto-immune diseases

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases
  • 03.02.03.02  Diagnostics / kits for the gastro enterology

Diagnostics / kits for the gastro enterology

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.15  Rapid tests - Immunochemistry

Rapid tests - Immunochemistry

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.15  Rapid tests - Immunochemistry
  • 03.02.15.02  Infectious disease tests

Infectious disease tests

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring
  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring
  • 03.02.16.01  Diagnostic agents / kits for determination of therapeutic drugs

Diagnostic agents / kits for determination of therapeutic drugs

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.01  Bacteriology

Bacteriology

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.01  Bacteriology
  • 03.04.01.06  Equipment for agrar production

Equipment for agrar production

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.06  Rapid tests - Microbiology

Rapid tests - Microbiology

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.01  Bacteriology - Infectious immunology

Bacteriology - Infectious immunology

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.05  Equipment and systems for microbiological diagnosis/virology
  • 03.05.05.01  Diagnostic agents / kits for microbiological diagnosis

Diagnostic agents / kits for microbiological diagnosis

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.05  Equipment and systems for microbiological diagnosis/virology
  • 03.05.05.03  Control material for microbiological diagnosis

Control material for microbiological diagnosis

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.06  Parasitology (Infectious immunology)

Parasitology (Infectious immunology)

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.08  Rapid tests - Infectious immunology

Rapid tests - Infectious immunology

Our products

Product category: Therapeutic drug monitoring

Rapid test for therapeutic drug monitoring of Infliximab

RIDA®QUICK IFX Monitoring as a rapid quantitative test at the point-of-care Therapeutic drug monitoring of infliximab and biosimilars using a test strip

More Less

Company news

Date

Topic

Download

Nov 2, 2016

First appearance: RIDA®QUICK IFX Monitoring as a rapid quantitative test at the point-of-care Therapeutic drug monitoring of infliximab and biosimilars using a test strip

Press release


First appearance: RIDA®QUICK IFX Monitoring as a rapid quantitative test at the point-of-care Therapeutic drug monitoring of infliximab and biosimilars using a test strip

Darmstadt, November 2016 – R-Biopharm AG (Hall 3 / B20) presents the RIDA®QUICK IFX Monitoring lateral flow assay as a novelty at the Medica 2016. Developed particularly for the point-of-care sector, this enzyme immunoassay is used for the quantitative detection of infliximab (IFX, Remicade®, TNFα blocker) and its biosimilars (Inflectra® and Remsima®) in human serum and plasma. This innovative rapid antibody test provides analysis results for therapeutic drug monitoring (TDM) to family doctors, gastroenterologists, therapists at clinics and outpatient care centers within 20 minutes. RIDA®QUICK IFX Monitoring is read out using the associated RIDA®QUICK SCAN II.

Due to the identical monoclonal antibody MA-IFX6B7, RIDA®QUICK IFX Monitoring is highly correlated with RIDASCREEN® IFX Monitoring, the ELISA (enzyme-linked immunosorbent assay) immunological detection method which has been validated in clinical studies - among others, in the trailblazing TAXIT study published at the end of 2015 by Belgian researchers of KU Leuven. This first prospective, randomized, and controlled study on individualized infliximab dosage in patients with chronic inflammatory bowel diseases documents that the monitoring of the active agent dose for maintaining a specific minimum level of infliximab in the maintenance phase of the therapy allows a more efficient and cost-effective use of the active agent.

Therapeutic drug monitoring of infliximab

Infliximab (IFX) is a chimeric antibody that is attributed to the so-called TNFα blockers. The active agent has been used worldwide in more than two million patients with Crohn’s disease and ulcerative colitis. The drug costs alone are up to €20,000 per patient per year. A specific active agent concentration must be present in the patient’s blood to be effective. Due to individual pharmacokinetics, humans show different IFX drug levels at an identical dosage – about 30 percent of the patients even show a loss of the drug’s efficacy. Using TDM, this can be checked and the number of patients with loss of efficacy can be reduced significantly and individual dosage setting can be optimized. TDM is a way to optimize IFX therapy and to reduce the costs of this treatment by 34 percent per patient.

R-Biopharm AG closely cooperates with KU Leuven (Belgium), globally renowned for its work in the field of gastroenerology, and is the own provider in Germany of the combination of the RIDASCREEN® IFX Monitoring ELISA test series and the corresponding rapid test, RIDA®QUICK IFX Monitoring. The RIDASCREEN® TDM test series has by now replaced the CE version of “in-house test” that were developed by KU Leuven.

About R-Biopharm:

R-Biopharm AG is one of the world's leading suppliers of reliable test systems for clinical diagnostics and animal feed and foodstuff analysis. Since 1988, R-Biopharm has developed innovative products of the highest quality, safety and efficiency. With a strong sense of responsibility for humans, animals, and the environment, long term experience, and a competence network of international partners and subsidiary companies,
R-Biopharm AG satisfies the wishes of its customers from trade, industry, and public institutions by continuously finding new solutions to current challenges. For more information, visit www.r-biopharm.com

Photos (free of charge, ©R-Biopharm AG):
- RIDA®QUICK IFX Monitoring product picture
- RIDA® QUICK SCAN II product picture

Contact for questions or more information:
Dr. Andrea Lennerz
Productmanager, Gastroenterology
Phone: +49 (0) 61 51 - 8102-0
Email: clinical.sales@r-biopharm.de

More Less

About us

Company details

The R-Biopharm group is a leading developer of solutions for clinical diagnostics and food and feed analysis. In both sectors the company's innovative test kits are relied upon for their analytical precision, a high priority when patient and consumer health is at stake.

The german mother company R-Biopharm AG was founded in 1988 as a subsidiary of Röhm GmbH in Darmstadt, Germany. In 1991 it was taken over by the present managing director, Dr. Ralf M. Dreher. Since 1996 R-Biopharm's quality management systems have been certified to the international standard ISO 9001. In 2003 the company gained ISO 13485 quality management certification. Today R-Biopharm AG has subsidiaries in the UK, USA, Italy, France, Spain, Latin America, Brasil and China and is also represented worldwide by an extensive network of more than 80 distributors.

In clinical diagnostics R-Biopharm possesses many years of sound experience, particularly in the field of infectological stool diagnostics but as well in the field of serological infection diagnostics and allergy diagnostics. 2006 the clinical product portfolio was extended by inovative test systems in the product lines tumor diagnostics and gastroenterology. For most clinical ELISA tests R-Biopharm provides flexible automation solutions that can be adapted to the specific needs of the individual laboratory. RIDASCREEN®, RIDA® and PentoCheck® were world-wide recognized trademarks of R-Biopharm. All distributed tests are validated and CE-marked.

R-Biopharm's distinctive policy of partner-ship and teamwork is an approach valued by its customers and research partners alike. The company's key objective is to be a dependable point of contact for customers, providing competent advice on every sector it serves. At R-Biopharm the future looks set to offer further exciting prospects in the fields of clinical diagnostics and food and feed analysis. The foremost challenge is to advance the development of new and versatile fast tests. These will shorten the time it takes to obtain results from a wide range of analytical procedures.

More Less

Company data

Sales volume

100-199 Mio US $

Export content

max. 50%

Number of employees

500-999

Foundation

1991

Area of business

Diagnostics